Showing all news

16 applications received for first Dementia Consortium deadline

The Dementia Consortium has got off to a great start, with 16 applications received for the first review deadline on 23 March. Of these, two have been asked to reapply with additional information and four have progressed to the second round of review, with decisions expected in July.

15 April 2014

New paper published in Drug Discovery Today

A new paper has been published in Drug Discovery Today entitled “Collaborative practices for medicinal chemistry research across the big pharma and not-for-profit interface” This is a joint publication between MRC Technology, AstraZeneca and Cancer Research Technology, which details how both MRC Technology and Cancer Research Technology have developed ways of progressing medicinal chemistry programmes working across pharma-academic collaborations.

11 February 2014

Student poster wins prize at Pharmacology 2013

MRC Technology undergraduate placement student Jamie Cartland presented a poster on quantitative pharmacology of the Dopamine DRD1 receptor at the Pharmacology 2013 meeting. The poster won the best student poster prize.

8 January 2014

MRC Technology and Oxford University Collaborate to Develop Novel Pain Therapeutics for Migraine

The collaboration will screen selective and potent potassium channel activators to develop novel therapeutic interventions in migraine. Drawing on MRC Technology’s commercialisation expertise in drug discovery, the project focusses on bringing to clinic more effective pain treatments arising from the work of Dr Cader’s group in identifying KCNK18, the first gene underlying typical migraine.

14 November 2013

New paper published

A paper entitled “Cloxyquin (5-chloroquinolin-8-ol) is an activator of the two-pore domain potassium channel TRESK” has been published in the journal Biochemical and Biophysical Research Communications. Full text of the article is available here.

13 November 2013
Showing all news